title: Development, characterization and evaluation of doxorubicin nanostructured lipid carriers for prostate cancer.
abstract: OBJECTIVE
  The purpose of this study was to develop an optimised formulation for a nanostructured lipid carrier (NLC) loaded with doxorubicin.
  
  
  METHODS
  A doxorubicin-loaded NLC was prepared using an emulsification solidification method. The Box-Behnken design response surface methodology was used to optimise formulations of the doxorubicin-loaded NLC.
  
  
  RESULTS
  The drug entrapment efficiency, drug loading efficiency, particle size, and zeta potential of the doxorubicin- loaded NLC were 74.18%, 13.28%, 170 nm, and -14.8 mV, respectively. Transmission electron microscopy of the optimised NLC showed spherical particles. Furthermore, the doxorubicin-loaded NLC was found to exhibit good therapeutic efficacy with remarkably improved oral bioavailability of doxorubicin.
  
  
  CONCLUSIONS
  The NLC system demonstrated potential for the targeted delivery of doxorubicin in prostate cancer.
authors.affiliation: Department of Urologic Surgery, Anyang District Hospital, Anyang, Henan 455000, China.
authors.forename: Hong-Wei
authors.initials: HW
authors.lastname: Zhang
authors.forename: Qiang
authors.initials: Q
authors.lastname: Dang
authors.forename: Zheng-Wei
authors.initials: ZW
authors.lastname: Zhang
authors.forename: Fu-Shun
authors.initials: FS
authors.lastname: Wu
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D001682:Biological Availability; D045744:Cell Line, Tumor; D004317:Doxorubicin / Q000008:administration & dosage* / Q000494:pharmacology; D004337:Drug Carriers; D016503:Drug Delivery Systems; D006801:Humans; D008055:Lipids / Q000008:administration & dosage; D008297:Male; D049329:Nanostructures; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D000903:Antibiotics, Antineoplastic; D004337:Drug Carriers; D008055:Lipids; D004317:Doxorubicin